ReCode Therapeutics, a clinical-stage genetic medicines company pioneering tissue-specific delivery technologies to advance the next generation of mRNA and gene correction therapeutics, announced today that it has secured more than $29 million in new financing. Alongside this financial update, the company also reported expanded investment from the Cystic Fibrosis Foundation (CF Foundation) and unveiled a new research collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX).
Dr. Shehnaaz Suliman, M.D., MBA, M.Phil., Chief Executive Officer of ReCode Therapeutics, emphasized the importance of these milestones in advancing genetic medicine.
“With continued support from organizations like the CF Foundation and our collaboration with Praxis, we are building on our momentum to deliver on the promise of genetic medicines for people living with genetic diseases who currently have limited or no effective treatments,” she said.
Strengthening Financial Position
The additional $29 million in financing strengthens ReCode’s balance sheet and provides capital to accelerate the advancement of its genetic medicines pipeline. This pipeline includes multiple investigational therapies focused on rare and life-threatening conditions such as cystic fibrosis (CF). By securing this new round of funding, ReCode is positioned to continue progressing both clinical and preclinical programs, ensuring that promising therapies move efficiently through development toward patients in need.
Expanded Partnership with the Cystic Fibrosis Foundation
A central component of ReCode’s clinical development strategy is its investigational therapy RCT2100, an inhaled mRNA treatment designed to address the underlying cause of CF. The therapy delivers a functional copy of the CFTR mRNA to lung cells, restoring production of the CFTR protein. Unlike current modulator therapies, which are ineffective for patients with certain rare or nonsense mutations, RCT2100 has the potential to benefit all individuals with CF.
The CF Foundation, which has been a longstanding supporter of this program, is increasing its commitment with an additional $3 million investment. This funding will specifically support ReCode’s ongoing Phase 2 clinical trial of RCT2100. To date, the Foundation has pledged up to $33 million across ReCode’s mRNA and gene editing programs, reflecting its confidence in the company’s innovative approach. For more details about the clinical trial, interested parties can visit www.CF-Clinical-Studies.com.
Collaboration with Praxis Precision Medicines
In addition to progress in cystic fibrosis, ReCode is expanding its technology into other therapeutic areas. The company has announced a research collaboration with Praxis Precision Medicines, Inc., a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders caused by imbalances in neuronal excitation and inhibition.
The partnership aims to leverage ReCode’s proprietary selective organ targeting (SORT) lipid nanoparticle (LNP) technology to identify a well-tolerated LNP formulation capable of enhancing the delivery of antisense oligonucleotides (ASOs) to brain regions that are currently underserved by existing delivery methods. This collaboration highlights the versatility of ReCode’s platform and its potential to expand beyond pulmonary diseases into neurological disorders.
Presence at Key Industry Conferences
ReCode leadership will be actively engaging with the global medical and scientific community in the months ahead. The company announced its participation at two major upcoming events:
- The European Respiratory Society (ERS) Congress, taking place in Amsterdam, Netherlands, from September 27 to October 1, 2025.
- The North American Cystic Fibrosis Conference (NACFC), scheduled for October 22–25, 2025, in Seattle, Washington.
These conferences provide opportunities for ReCode to share updates, foster collaborations, and engage directly with clinicians, researchers, and patient advocacy organizations.
Looking Ahead
With the infusion of new capital, expanded support from the CF Foundation, and the launch of its collaboration with Praxis, ReCode Therapeutics continues to advance its mission of delivering transformative genetic medicines. By leveraging its tissue-specific delivery platform, the company aims to overcome one of the greatest barriers in genetic medicine—achieving safe, effective, and targeted delivery of therapies to the right cells and tissues.
As ReCode builds on this momentum, its progress underscores a broader shift in the field of genetic medicine: the move toward therapies that can benefit patient populations who have historically been underserved by existing treatments.
About ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues, and cells implicated in disease, enabling improved efficacy and potency.
ReCode’s lead programs include RCT2100 for the treatment of the 10% of people with cystic fibrosis who have genetic mutations in the CFTR gene that do not respond to currently approved CFTR modulators or those intolerant of approved CFTR modulators, and RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated with the SORT LNP delivery platform.
For more information, visit www.recodetx.com and follow us on LinkedIn and Instagram.
